Hematologic Oncology Review 2014

Elm

& C

arlton Streets

Buffalo, N

Y 14263

27627 (3/14)

S P E A K E R S

Invited Speakers:

Renier Brentjens, MD, PhD Memorial Sloan Kettering Cancer Center

Teresa Gentile, MD, PhD SUNY Upstate Medical University at Syracuse

Nicole Lamanna, MD Columbia University Medical Center

Roswell Park Cancer Institute Faculty:

Myron Czuczman, MD

Elizabeth Griffiths, MD

Francisco Hernandez Ilizaliturri, MD

Sarah Holstein, MD, PhD

Philip McCarthy, MD

Vishala Neppalli, MD

Meir Wetzler, MD, FACP

R E G I S T R A T I O N F E E S : $ 45 . . . . . Physicians and pharmacists

$ 25 . . . . . All other health care providers

$ 345 . . . . . Pharmaceutical Industry Employees

For more information and to register, go to www.roswellpark.edu/CMEConferences . If you have any questions, contact Denise Hammell at denise .hammell@roswellpark .org or (716) 845-5706 .

This program is supported in part by educational grants from:

S A T U R D A Y

May 3, 2014 8am – 12:30pm

Holiday Inn441 Electronics Parkway, Liverpool, NY 13088

REGISTER ONLINE AT WWW.ROSWELLPARK.EDU/CMECONFERENCES

This program is designed for hematologists, oncologists, nurses, nurse practitioners, physician assistants and oncology-focused pharmacists . New clinically relevant research findings are reported each year at large national hematology meetings . While community oncologists may learn about these findings in a timely manner, it may take months before strategies to effectively put this new knowledge into practice are developed . This conference will provide opportunities to focus on the most clinically relevant research findings presented at recent national events and to better understand how to apply this information in specific patient cases .

We hope that you will join us for a morning of collegial discussion on the challenges of caring for patients with hematologic malignancies.

A C C R E D I T A T I O N - A M A & A A N PRoswell Park Cancer Institute is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians .

Roswell Park Cancer Institute designates this live educational activity for a maximum of 4 .25 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity .

This program is pending approval by the American Association of Nurse Practitioners .

E D U C A T I O N A L O B J E C T I V E S

Following this program, participants should be able to:

• Determine which biomarkers are clinically useful in guiding treatment selection when using risk stratification for newly diagnosed MCL patients .

• Identify changes that have been adopted in the clinical management of less common types of aggressive DLBCL subtypes (i .e . Primary mediastinal lymphoma, double-hit DLBCL, gray zone lymphoma) .

• Explain the common side effects associated with the use of novel agents approved for the treatment of T-cell Lymphoma, and how they are optimally managed .

• Describe the role of maintenance therapy in MM patients and how long maintenance therapy is necessary .

• Define the optimal treatment of newly diagnosed ALL patients .

• Ascertain how the use of novel monoclonal antibodies targeting CD20 will change the treatment paradigm of CLL patients .

• Explain how gene expression profiling studies are improving our knowledge in the biology of MDS .

• Define who is at risk to develop resistance to tyrosine kinase inhibitor .

• Identify novel combination strategies being used in the management of relapsed/refractory MM patients .

P R O G R A M T O P I C S

• Emerging Approaches in the Manage- ment of Patients with Chronic Myeloid Leukemia (CML)

• Progress in the Management of MDS

• Clinical Practice Changes in the Manage-ment of Acute Lymphoid Leukemia (ALL)

• Leukemia Clinical Practice Round Table

• Clinical Practice Changes in the Front-line Management of Transplant Eligible MM Patients: the Evolving Role Post-transplant Maintenance Programs

• Clinical Practice Changes in the Front-line Management of Transplant Ineligible MM Patients: the Evolving Role of Maintenance Programs

• Managing Relapsed/Refractory Multiple Myeloma: How to Optimize Recently Approved Targeted Agents

• Myeloma Clinical Practice Round Table

• Clinical Practice Changes in the Manage-ment of Mantle Cell Lymphoma (MCL)

• Optimizing the Clinical Outcome of Diffuse Large B-cell Lymphoma

• Clinical Practice Changes in the Manage-ment of T-cell Lymphoma Patients

• Emerging Approaches in the Management of Patients with Chronic Lymphocytic Leukemia

• Lymphoma Clinical Practice Round Table